Results 211 to 220 of about 410,667 (361)

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Patients with alopecia areata received etrasimod 2 mg, 3 mg or placebo oncedaily for 24 weeks, followed by a 28‐week open‐label extension period. Overall, etrasimod 2 mg and 3 mg were safe and well tolerated in patients; their efficacy was numerically higher than placebo and appeared to be dose dependent.
B. King, N. Mesinkovska, M. Senna, X. Luo, J. Minkiewicz, A. Selfridge   +5 more
wiley   +1 more source

Intravitreal Triamcinolone Reinjection for Refractory Diabetic Macular Edema [PDF]

, 2006
Alireza Ramezani, Hamid Ahmadieh, Tabatabaei Homa   +2 more
openalex   +1 more source

Activatable Photosensitizers: From Fundamental Principles to Advanced Designs

Angewandte Chemie, Volume 137, Issue 15, April 7, 2025.
Basic concepts of designing activatable photosensitizers are established in this Review by closely examining quenching mechanisms and bioresponsive constructs essential for their function. New strategies developed in the last five years that address the shortcomings of conventional activatable photosensitizers and which enhance selectivity are also ...
Nahyun Kwon, Hanyi Weng, Maneesha A. Rajora, Gang Zheng   +3 more
wiley   +2 more sources

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema [PDF]

, 2007
J. Fernando Arévalo, Jans Fromow-Guerra, Hugo Quiroz–Mercado, J. García Sánchez, Lihteh Wu, Maurício Maia, María H. Berrocal, A. Solis–Vivanco, Michel Eid Farah   +8 more
openalex   +1 more source

Central Serous Chorioretinopathy Diagnosed by Emergency Practitioner‐Performed Ocular Point‐Of‐Care Ultrasonography

Australasian Journal of Ultrasound in Medicine, Volume 28, Issue 2, May 2025.
ABSTRACT Introduction Central serous chorioretinopathy (CSCR) is a common cause of acute, monocular vision loss amongst men aged 40–50 years. Diagnosis is typically multimodal, requiring advanced ophthalmic imaging. These techniques are not readily available in acute care settings.
Christian P. Pappas, Matthew Watson, Christopher Harrington, Katherine Masselos   +3 more
wiley   +1 more source

Reproducibility of Macular Thickness and Volume Using Zeiss Optical Coherence Tomography in Patients with Diabetic Macular Edema [PDF]

, 2007
Magdalena G. Krzystolik, Strauber Sf, Aiello Lp, Beck Rw, Berger Bb, Bressler Nm, Browning DJ, Chambers Rb, Danis Rp, Davis, Adam R. Glassman, Gonzalez Vh, Greenberg Pb, Gross Jg, Kim Min Je, Craig Kollman   +15 more
openalex   +1 more source

Vitrectomy in Small idiopathic MAcuLar hoLe (SMALL) study: Internal limiting membrane peeling versus no peeling

Acta Ophthalmologica, Volume 103, Issue 3, Page e156-e164, May 2025.
Abstract Purpose To compare vitrectomy with and without internal limiting membrane (ILM) peeling in small idiopathic macular holes. Methods Retrospective multicentre study including consecutive eyes with ≤250 μm idiopathic macular hole treated with vitrectomy. The primary outcome was hole closure rate.
Paola Marolo, Paolo Caselgrandi, Matteo Fallico, Guglielmo Parisi, Enrico Borrelli, Federico Ricardi, Francesco Gelormini, Luca Ceroni, Michele Reibaldi, SMALL Study Group, Tommaso Micelli Ferrari, Massimo Lorusso, Vito Primavera, Gianluigi Giuliani, Cesare Mariotti, Marco Lupidi, Luca Ventre, Giulia Pintore, Lorenzo Motta, Matteo Ripa, Francesco Boscia, Giacomo Boscia, Mario R Romano, Mariantonia Ferrara, Kacerik Miroslav, Daniele Marchina, Barbara Parolini, Enrico Peiretti, Viola Marchiori, Roberto Dell’Omo, Marzia Affatato, Teresio Avitabile, Andrea Russo, Antonio Longo, Vincenzo Scorcia, Adriano Carnevali, Rodolfo Mastropasqua, Lisa Toto, Agostino Salvatore Vaiano, Riccardo Merli, Marco Mura, Marco Pellegrini, Fabrizio Giansanti, Cristina Nicolosi, Matteo Badino, Nicola Pallozzi Lavorante, Maria T. Sandinha, Francesco Maria D’Alterio, Mario Damiano Toro, Robert Rejdak, Paolo Chelazzi, Claudia Azzolini, Francesco Viola, Caterina Donà, Matteo Giuseppe Cereda, Marco Casaluci, Marco Codenotti, Lorenzo Iuliano, Grazia Pertile, Daniele Sindaco, Stefano De Cillà, Andrea Muraca, Vincenza M.E. Bonfiglio, Maria Vadalà, Alberto La Mantia, Viviana Randazzo, Tito Fiore, Gianluigi Tosi, Rino Frisina, Chiara Angeli, Marco Coassin, Mariateresa Laborante, Tommaso Rossi, Pamela Cosimi, Stanislao Rizzo, Matteo Mario Carlà, Magda Gharbiya, Giuseppe Maria Albanese, Luigi Caretti, Edoardo Angelini, Gian Marco Tosi, Tommaso Bacci, David H Steel, Nikolaos Dervenis, Iordanis Vagiakis, Daniele Tognetto, Marco Rocco Pastore, Francesco Faraldi, Carlo Alessandro Lavia, Paolo Lanzetta, Daniele Veritti, Leopoldo Rubinato, Paolo Radice, Andrea Govetto   +93 more
wiley   +1 more source

Triamcinolona subtenoniana en el edema macular diabético Subtenon triamcinolone in the diabetic macular edema

Revista Cubana de Oftalmología, 2009
INTRODUCCIÓN: La prevalencia de la retinopatía diabética está determinada por el tipo de diabetes mellitus y por el tiempo de evolución de la enfermedad.
Eddy Mesa Hernández, Odalis González Peña, Isabel Medina Rodríguez, Rafael González Díaz, Emoe Pérez Muñoz   +4 more
doaj  

Deep Learning Ensemble for Predicting Diabetic Macular Edema Onset Using Ultra-Wide Field Color Fundus Image [PDF]

arXiv
Diabetic macular edema (DME) is a severe complication of diabetes, characterized by thickening of the central portion of the retina due to accumulation of fluid. DME is a significant and common cause of visual impairment in diabetic patients. Center-involved DME (ci-DME) is the highest risk form of disease because fluid extends close to the fovea which
arxiv  

Early versus Late Intravitreal Triamcinolone Acetonide for Macular Edema associated with Branch Retinal Vein Occlusion [PDF]

, 2007
Joo Youn Oh, Je Hyun Seo, Jae Kyoun Ahn, Jang Won Heo, Hum Chung   +4 more
openalex   +1 more source